Fig. 3. (A) Overall (OS) and (B) progression-free survival (PFS) after decitabine treatment. The median OS and PFS of all patients were 502 days and 201 days (95% CI, 50 to 351 days), respectively, from the starting date of the first decitabine treatment. CI, confidence interval.